The Technology Development Board (TDB), Department of Science & Technology, Government of India, has entered into an agreement with M/s Griva Healthcare Pvt. Ltd., Vishakhapatnam to support the manufacturing and commercialization of 'GrivaVision', an indigenously developed portable digital colposcope with AI-assisted capabilities for early detection of cervical pre-cancerous lesions. The support will enable the company to establish manufacturing capabilities at Kollam, Kerala, facilitating commercial-scale production and wider deployment of the technology.
GrivaVision integrates a high-definition camera, in-built display, user-friendly interface, advanced optics, and indigenous AI-enabled software into a portable diagnostic platform designed for visualization of the vaginal canal and examination of cervical lesions. The system assists gynaecologists in identifying pre-cancerous abnormalities during routine clinical examinations and is designed in accordance with WHO-approved Automated Visual Evaluation (AVE) standards. The software is ABDM-compliant, enabling integration with India's digital health ecosystem.
The product is classified as a Class B non-invasive medical device and carries a CDSCO Class B manufacturing licence, being developed in accordance with ISO 13485 quality standards. The hardware architecture is proprietary and has been patented in India by Griva Healthcare. The company is currently undertaking R&D activities at AIC-AMTZ Medivalley, Visakhapatnam, with the TDB-supported project enabling transition toward commercial manufacturing.
A key aspect of the project is its focus on indigenous development and localization, with more than 50% of product components currently sourced indigenously. Commercialization at scale is expected to strengthen the domestic medical device value chain and create a cost-effective Indian alternative in cervical cancer diagnostics. The technology aims to make cervical cancer screening more accessible and affordable, particularly across primary and community healthcare settings, while reducing dependence on imported diagnostic equipment.
Shri Rajesh Kumar Pathak, Secretary, TDB, emphasized that early detection can make a decisive difference in addressing cervical cancer and that TDB's support aims to take home-grown innovations from technology development to commercial manufacturing. The leadership of Griva Healthcare expressed gratitude for TDB's support, noting that the assistance will enable the company to expand access to AI-assisted cervical cancer screening, particularly in regions where access to specialized diagnostic infrastructure remains limited.